Monday
March 10, 2025
8:00 AM ET
UroGen Pharma Reports Fourth Quarter and Full Year 2024 Financial Results and Announces Updated 18-Month Duration of Response (DOR) of 80.6% from the Phase 3 ENVISION Trial of UGN-102
Thursday
February 27, 2025
8:00 AM ET
UroGen Pharma to Report Fourth Quarter and Full-Year 2024 Financial Results on Monday, March 10, 2025
Wednesday
November 6, 2024
8:00 AM ET
UroGen Pharma Reports 2024 Third Quarter Financial Results and Business Highlights, Including the Potential Launch of UGN-102 in 2025
Wednesday
October 30, 2024
8:00 AM ET
UroGen Pharma to Report Third Quarter Financial Results on Wednesday, November 6, 2024